Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
International Journal of Molecular Sciences · 19.06.2024 · 25 (12) · 6733
DOI: 10.3390/ijms25126733 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.06.2024. Verfasst von Christopher Chang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Warren Alpert Medical School, Brown University, Providence, RI 02912, USA. Hauptthemen laut MEDLINE: Glioblastoma, Neoplasm Recurrence, Local, Brain Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, DFCI/Kiki Leptomeningeal Disease Grant, German Research Foundation.
Abstract (Originalsprache)
Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6–9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, and epigenetic modifications. Contemporary standard-of-care (surgery, radiation, chemotherapy, and tumor treating fields) helps to control the primary tumor but rarely prevents relapse. Cytoreductive treatment such as surgery has shown benefits in recurrent glioblastoma; however, its use remains controversial. Several innovative treatments are emerging for recurrent glioblastoma, including checkpoint inhibitors, chimeric antigen receptor T cell therapy, oncolytic virotherapy, nanoparticle delivery, laser interstitial thermal therapy, and photodynamic therapy. This review seeks to provide readers with an overview of (1) recent discoveries in the molecular basis of recurrence; (2) the role of surgery in treating recurrence; and (3) novel treatment paradigms emerging for recurrent glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
- Harvard Medical School, Harvard University, Boston, MA 02115, USA.
- Department of Neurosurgery, University of Rostock, 18055 Rostock, Germany.
- Department of Neurosurgery, University of Texas Medical Branch, Galveston, TX 77555, USA.
- Division of Biology and Medicine, Brown University, Providence, RI 02912, USA.
ORCID-Profile: Christopher Chang, Velina S Chavarro, Jakob V E Gerstl, Sarah E Blitz, Lennard Spanehl, Florian A Gessler, Pierpaolo Peruzzi, Joshua D Bernstock
Förderung
- NIH HHS
- DFCI/Kiki Leptomeningeal Disease Grant
- German Research Foundation
- National Institutes of Health
Zitieren
APA
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., Mazzetti, D., Gessler, F. A., Arnaout, O., Smith, T. R., Friedman, G. K., Peruzzi, P., & Bernstock, J. D. (2024). Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms. International Journal of Molecular Sciences, 25(12), 6733. https://doi.org/10.3390/ijms25126733
Vancouver
Chang C, Chavarro VS, Gerstl JVE, Blitz SE, Spanehl L, Dubinski D, et al. Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms. International Journal of Molecular Sciences. 2024;25(12):6733. doi:10.3390/ijms25126733
BibTeX
@article{Chang2024,
author = {Chang, Christopher and Chavarro, Velina S and Gerstl, Jakob V E and Blitz, Sarah E and Spanehl, Lennard and Dubinski, Daniel and Valdes, Pablo A and Tran, Lily N and Gupta, Saksham and Esposito, Luisa and Mazzetti, Debora and Gessler, Florian A and Arnaout, Omar and Smith, Timothy R and Friedman, Gregory K and Peruzzi, Pierpaolo and Bernstock, Joshua D},
title = {Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {12},
pages = {6733},
doi = {10.3390/ijms25126733}
}
EUVIMED